Results 41 to 50 of about 3,819 (202)
Gastrointestinal bleeding in patients on novel oral anticoagulants: Risk, prevention and management [PDF]
, 2017 Novel oral anticoagulants (NOACs), which include direct thrombin inhibitor (dabigatran) and direct factor Xa inhibitors (rivaroxaban, apixaban and edoxaban), are gaining popularity in the prevention of embolic stroke in non-valvular atrial fibrillation ...
Cheung, KS, Leung, WK
core +1 more source
Interventional radiology treatments for iatrogenic severe bleeding during percutaneous coronary interventions [PDF]
, 2018 Purpose: Interventional cardiology and interventional radiology are separate medical disciplines in which intra-arterial contrast media are used. Interventional cardiology has resigned from many types of treatment techniques that are now used and ...
Brzozowski, Krzysztof +5 more
core +1 more source
Two Dabigatran Fast Reversals in a 4-month Period – a Case Report
European Journal of Case Reports in Internal Medicine, 2019 Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation in life-threatening bleeding or urgent surgery in patients with non-valvular atrial fibrillation (nvAF).
Vítor Fagundes, Mari Mesquita
doaj +1 more source
Unraveling the Pharmacokinetic Interaction of Ticagrelor and MEDI2452 (Ticagrelor Antidote) by Mathematical Modeling [PDF]
, 2016 The investigational ticagrelor-neutralizing antibody fragment, MEDI2452, is developed to rapidly and specifically reverse the antiplatelet effects of ticagrelor.
Almquist, Joachim +9 more
core +1 more source
New oral anticoagulants and their reversal agents [PDF]
, 2018 Atrial fibrillation is a commonly encountered pathology in medical practice, and its prevalence has shown a continuous rise over the past years. Atrial fibrillation has a significant impact on patients\u27 quality of life, not only due to the standard ...
Bodean, Oana +9 more
core +1 more source
Transfusion, EarlyView.Abstract Background Oral factor Xa (FXa) inhibitors are anticoagulants with no approved reversal agent for use before urgent invasive procedures. Four‐factor prothrombin complex concentrate (4F‐PCC) is used off‐label for this despite limited evidence regarding its effectiveness and safety.
Mohammad Shamiea +8 more
wiley +1 more source
Frontiers in Aging Neuroscience, 2021 Background: As there is a growing concern about the cerebral embolism events secondary to non-valvular atrial fibrillation (NVAF), novel oral anticoagulant (NOAC) has been more and more widely used as an anticoagulation treatment for the prevention of ...
Dan Xie +7 more
doaj +1 more source
US Food and Drug Administration Approvals of Drugs and Devices Based on Nonrandomized Clinical Trials: A Systematic Review and Meta-analysis [PDF]
, 2019 IMPORTANCE The size of estimated treatment effects on the basis of which the US Food and Drug Administration (FDA) has approved drugs and devices with data from nonrandomized clinical trials (non-RCTs) remains unknown.OBJECTIVES To determine how often ...
Chalmers, Iain +5 more
core +1 more source
Clinical Cardiology, Volume 49, Issue 4, April 2026.Direct Oral Anticoagulants (DOACs) were associated With lower rates of cerebrovascular ischemic events and major bleeding compared With Vitamin K antagonists in non‐valvular atrial fibrillation, With similar mortality. These findings support DOACs as the preferred anticoagulant strategy for stroke prevention in contemporary clinical practice.
Anam Nasir +8 more
wiley +1 more source
Consensus Guides on Stroke Thrombolysis for Anticoagulated Patients from Japan: Application to Other Populations [PDF]
Journal of Stroke, 2018 Development of direct oral anticoagulants and their antidotes has led to the need to reconsider the eligibility of acute stroke patients who have been taking oral anticoagulants for intravenous thrombolysis.
Kazunori Toyoda +2 more
doaj +1 more source